3M, maker of Post-it notes, industrial coatings and ceramics, is cutting about 2,500 manufacturing jobs worldwide as it looks to align itself with adjusted production volumes.
The company announced last month that it will exit per- and polyfluoroalkyl substance manufacturing by the end of 2025. The so-called forever chemicals are used in nonstick frying pans, water-repellent sports gear, stain-resistant rugs, cosmetics and countless other consumer products.
3M Co. also reported fourth-quarter earnings of $541 million, or 98 cents per share. Its adjusted profit was $2.28 per share. That's below the $2.34 per share that analysts polled by Zacks Investment Research predicted.
Revenue for the St Paul, Minnesota-based company totaled $8.08 billion in the period, beating Wall Street's estimate of $8.04 billion.
Chairman and CEO Mike Roman said in a statement that 3M experienced rapid declines in consumer-facing markets and a significant slowdown in China due to COVID-19-related disruptions. He said the company anticipates macroeconomic challenges continuing this year.
Looking ahead to the full year, the company expects 2023 adjusted earnings per share of $8.50 to $9, versus $9.88 per share in 2022.
Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and what’s next for modern vet medicine.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
